Abstract
In this study, we investigated the in vitro cytotoxicity and in vivo biosafety of reinforced polylactide (PLA) composites with hyaluronic acid-chitosan (HACS) complex and β-tricalcium phosphate (β-TCP) powder. The cytotoxicity of HACS/PLA (with β-TCP) composites was almost the same as that of neat PLA indicating that HACS/PLA (with β-TCP) composites did not have toxic effects. In in vivo biosafety tests using X-ray and micro-CT imaging, HACS/PLA (with β-TCP) composites did not show any fracture during 20 weeks of implantation in the tibia and femur of rabbits. The HACS/PLA (with β-TCP) composites did not induce severe inflammatory responses such as recruitment of macrophages around the implantation site, as assessed by H&E and immune staining of biopsy samples, for 6 weeks after insertion into SD rats. Addition of β-TCP powder to HACS/PLA composite enhanced bone induction and regeneration. The HACS/PLA composites prepared in the present study have potential maxillofacial and orthopedic applications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
